miR‑361‑5p regulates ovarian cancer cell proliferation and apoptosis by targeting TRAF3

Ling,Jianmei; He,Panwen

doi:10.3892/etm.2021.9632

miR‑361‑5p regulates ovarian cancer cell proliferation and apoptosis by targeting TRAF3

Authors:
- Jianmei Ling
- Panwen He
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Nantong Maternal and Child Health Care Hospital, Nantong, Jiangsu 226000, P.R. China, Clinical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430010, P.R. China
Published online on: January 11, 2021 https://doi.org/10.3892/etm.2021.9632
Article Number: 199
Copyright: © Ling et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing body of evidence has demonstrated that the abnormal expression of microRNAs (miRNAs) participate in the development and progression of ovarian cancer. miR‑361‑5p has been reported to serve as a tumor suppressor or oncogene in a number of different human cancer types. In the current study, it was indicated that miR‑361‑5p was highly expressed in ovarian cancer tissues. Compared with human ovarian epithelial cells HOSEpiC, miR‑361‑5p was upregulated in ovarian cancer cell lines, including in ES‑2 and SKOV3 cells. The binding sites between TNF receptor‑associated factor 3 (TRAF3; a member of the TRAF family of cytoplasmic adaptor proteins) and miR‑361‑5p were predicted using TargetScan, and a dual luciferase reporter gene assay verified the result. Subsequently, a reverse transcription‑quantitative PCR assay and western blot assay indicated that TRAF3 was downregulated in ovarian cancer tissues and cell lines. It was demonstrated that miR‑361‑5p inhibitor significantly reduced the viability of SKOV3 cells and induced apoptosis. However, all changes were reversed by TRAF3 silencing. Furthermore, it was demonstrated that miR‑361‑5p inhibitor decreased the expression of p‑p65 in SKOV3 cells, indicating the inhibition of the NF‑kB signaling pathway. In conclusion, miR‑361‑5p may regulate the proliferation and apoptosis of ovarian cancer cells by targeting TRAF3. Therefore, targeting miR‑361‑5p may exhibit therapeutic potential in the treatment of ovarian cancer.

View Figures

View References

1	Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013.PubMed/NCBI View Article : Google Scholar
2	Bearfoot JL, Choong DY, Gorringe KL and Campbell IG: Genetic analysis of cancer-implicated MicroRNA in ovarian cancer. Clin Cancer Res. 14:7246–7250. 2008.PubMed/NCBI View Article : Google Scholar
3	Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood W III, Becker KG and Morin PJ: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 3(e2436)2008.PubMed/NCBI View Article : Google Scholar
4	Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X and Tang H: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 276:5537–5546. 2009.PubMed/NCBI View Article : Google Scholar
5	Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H and Katsaros D: MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol. 122:366–371. 2011.PubMed/NCBI View Article : Google Scholar
6	Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P and Stoffel M: A pancreatic islet-specifc microRNA regulates insulin secretion. Nature. 432:226–230. 2004.PubMed/NCBI View Article : Google Scholar
7	Wang Q, Liu N, Yang X, Tu L and Zhang X: Small RNA-mediated responses to low- and high-temperature stresses in cotton. Sci Rep. 6:35558–35571. 2016.PubMed/NCBI View Article : Google Scholar
8	Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005.PubMed/NCBI View Article : Google Scholar
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
10	Wang Y, Chen F, Zhao M, Yang Z, Zhang S, Ye L, Gao H and Zhang X: MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3'UTR. Biochem Biophys Res Commun. 480:455–460. 2016.PubMed/NCBI View Article : Google Scholar
11	Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR, Han XJ, Zhu SJ, Wang SM, Li YH and Zhang W: miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer. 16(806)2016.PubMed/NCBI View Article : Google Scholar
12	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View Article : Google Scholar
13	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005.PubMed/NCBI View Article : Google Scholar
14	Wei J, Zhang L, Li J, Zhu S, Tai M, Mason CW, Chapman JA, Reynolds EA, Weiner CP and Zhou HH: MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer. J Ovarian Res. 10(33)2017.PubMed/NCBI View Article : Google Scholar
15	Xie HH, Huan WT, Han JQ, Ren WR and Yang LH: MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2. Biol Res. 52:18–27. 2019.PubMed/NCBI View Article : Google Scholar
16	Cui W, Li Y, Xu K, Chen G, Lu X, Duan Q and Kang Z: miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA. Biochem Biophys Res Commun. 479:901–906. 2016.PubMed/NCBI View Article : Google Scholar
17	Ma F, Zhang L, Ma L, Zhang Y, Zhang J and Guo B: MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1. J Exp Clin Cancer Res. 36(158)2017.PubMed/NCBI View Article : Google Scholar
18	Chen SF, Liu Z, Chaurasiya S, Dellinger TH, Lu J, Wu X, Qin H, Wang J, Fong Y and Yuan YC: Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. Oncotarget. 9:20451–20466. 2018.PubMed/NCBI View Article : Google Scholar
19	Ma J, Jing XT, Chen Z, Duan Z and Zhang Y: MiR-361-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at RPL22L1 and c-Met signaling. Int J Clin Exp Pathol. 11:2588–2596. 2018.PubMed/NCBI
20	Häcker H, Tseng PH and Karin M: Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol. 11:457–468. 2011.PubMed/NCBI View Article : Google Scholar
21	Yi Z, Lin WW, Stunz LL and Bishop GA: Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth Factor Rev. 25:147–156. 2014.PubMed/NCBI View Article : Google Scholar
22	Gong J, Li ZZ, Guo S, Zhang XJ, Zhang P, Zhao GN, Gao L, Zhang Y, Zheng A, Zhang XF, et al: Neuron-specifc tumor necrosis factor receptor-associated factor 3 is a central regulator of neuronal death in acute ischemic stroke. Hypertension. 66:604–616. 2015.PubMed/NCBI View Article : Google Scholar
23	Zhu CL and Gao GS: MiR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator. Asian Pac J Cancer Prev. 15:8595–8601. 2014.PubMed/NCBI View Article : Google Scholar
24	Zhu L and Fang J: The structure and clinical roles of MicroRNA in colorectal cancer. Gastroenterol Res Pract. 2016(1360348)2016.PubMed/NCBI View Article : Google Scholar
25	Shukla KK, Misra S, Pareek P, Mishra V, Singhal B and Sharma P: Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer. Urol Oncol. 35:92–101. 2017.PubMed/NCBI View Article : Google Scholar
26	Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer-an emerging concept. EBioMedicine. 12:34–42. 2016.PubMed/NCBI View Article : Google Scholar
27	Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, Fang Y, Lin X, Xu Y, Xu W, et al: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 135:1286–1296. 2014.PubMed/NCBI View Article : Google Scholar
28	Gadducci A, Sergiampietri C, Lanfredini N and Guiggi I: Micro-RNAs and ovarian cancer: The state of art and perspectives of clinical research. Gynecol Endocrinol. 30:266–271. 2014.PubMed/NCBI View Article : Google Scholar
29	Salem M, Shan Y, Bernaudo S and Peng C: miR-590-3p targets cyclin G2 and FOXO3 to promote ovarian cancer cell proliferation, invasion, and spheroid formation. Int J Mol Sci. 20(E1810)2019.PubMed/NCBI View Article : Google Scholar
30	Zhou J, Zhang C, Zhou B and Jiang D: miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-β/Smad4 signaling pathway. Int J Mol Med. 43:1734–1746. 2019.PubMed/NCBI View Article : Google Scholar
31	Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GF, Gerber AP and Detmar M: The expression levels of MicroRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS One. 7(e49568)2012.PubMed/NCBI View Article : Google Scholar
32	Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, Jiang L, Zhang X, et al: MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6 (STAT6). Biochem Biophys Res Commun. 445:151–156. 2014.PubMed/NCBI View Article : Google Scholar
33	Häcker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Häcker G, et al: Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 439:204–207. 2006.PubMed/NCBI View Article : Google Scholar
34	Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, Perry A and Cheng G: Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature. 439:208–211. 2006.PubMed/NCBI View Article : Google Scholar
35	Xie P: TRAF molecules in cell signaling and in human diseases. J Mol Signal. 8(7)2013.PubMed/NCBI View Article : Google Scholar
36	Rehei AL, Zhang L, Fu YX, Mu WB, Yang DS, Liu Y, Zhou SJ and Younusi A: MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol Sci. 22:5156–5164. 2018.PubMed/NCBI View Article : Google Scholar